Compare BEEP & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BEEP | BWAY |
|---|---|---|
| Founded | 2015 | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Blank Checks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 129.4M | 337.9M |
| IPO Year | N/A | 2019 |
| Metric | BEEP | BWAY |
|---|---|---|
| Price | $2.61 | $17.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $6.75 | ★ $23.50 |
| AVG Volume (30 Days) | ★ 77.6K | 62.4K |
| Earning Date | 11-10-2025 | 11-11-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 213.09 |
| EPS | N/A | ★ 0.13 |
| Revenue | $35,470,000.00 | ★ $49,094,000.00 |
| Revenue This Year | N/A | $330.76 |
| Revenue Next Year | $2.97 | $22.24 |
| P/E Ratio | ★ N/A | $51.80 |
| Revenue Growth | N/A | ★ 27.08 |
| 52 Week Low | $2.50 | $7.84 |
| 52 Week High | $4.86 | $18.18 |
| Indicator | BEEP | BWAY |
|---|---|---|
| Relative Strength Index (RSI) | 38.54 | 54.19 |
| Support Level | $2.73 | $15.97 |
| Resistance Level | $3.30 | $17.38 |
| Average True Range (ATR) | 0.25 | 0.68 |
| MACD | 0.01 | -0.10 |
| Stochastic Oscillator | 13.75 | 51.25 |
Mobile Infrastructure Corp focuses on acquiring, owning, and leasing parking facilities and related infrastructure, including parking lots, parking garages and other parking structures throughout the United States. It operates in a single reportable segment: parking. The parking segment derives revenue from managed property revenue and rental income at parking facilities. The company provide access to property and space for the parker's vehicle and charges fees that vary based on the level of usage. The company derives all of its revenue domestically.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.